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Abstract Germline mutations in the CDKN2A gene are
associated with an increased risk of malignant melanoma
and pancreatic cancer. In order to find out if the behavior
pattern in families with a CDKN2A mutation is similar to
what we previously have described in families with a
BRCA1 mutation, we have studied the uptake of genetic
services in probands and their relatives. We describe
whether they attend genetic counseling when invited,
whether they want a mutation test after being counseled
and whether they adhere to recommendations for surveil-
lance. 66 % (95/144) of first-degree relatives to mutation
carriers contacted us within the study period. 98 % (126/
128) of all relatives who came for genetic counseling
decided on genetic testing for their family’s mutation, and
93 % (66/71) of all mutation carriers wanted referral to
yearly skin examinations. Female relatives had a signifi-
cantly higher uptake of genetic services compared to
males, similar to the findings in families with a BRCA1
mutation. Uptake of genetic services in general in families
with a CDKN2A mutation is high. Females seem to have a
higher interest in genetic testing than males, regardless of
gene mutated.
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Introduction
For many cancer syndromes there are established surveil-
lance guidelines. They have been extensively evaluated
and many have been proven efficient. The goal is preven-
tion, early diagnosis and cure. The cancer syndromes
caused by germline mutations in CDKN2A and CDK4 have
not been studied to the same degree. In our cancer genetic
clinic we provide genetic counseling, genetic testing and
follow-up for all hereditary cancer syndromes. We wish to
determine whether we reach all at-risk individuals in
families with a CDKN2A mutation in order to inform them
of the possibility of genetic testing and surveillance.
After the identification of CDKN2A [1] and CDK4 [2]
genetic testing of families with hereditary malignant mel-
anoma is possible. Genetic testing for disease-causing
mutations has been available for many years for numerous
cancer syndromes and uptake of genetic testing has been
evaluated for several of these. In breast and ovarian cancer
families, for example, early evaluation of uptake of genetic
testing ranged from 43 to 80 % [3–5]. In our own clinic,
studying genetic testing for a known BRCA1 mutation in a
population of at-risk females, 30 years or older, showed
that 82 % pursued genetic testing [6]. In some reports,
including ours, females were shown to be significantly
more interested in genetic testing than males [4, 6–8]. This
was believed to be due to the higher cancer risks for
women in these families.
Having mutations in of CDKN2A and CDK4 is associ-
ated with a significant increased risk of malignant mela-
noma. Early diagnosis is crucial for the prognosis of
cutaneous malignant melanoma (CMM). The actual life-
time risk of developing CMM among mutation carriers is
high, but varies greatly due to many factors including other
host characteristics and geographical differences [9]. This
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is related to both genetic and environmental factors. For
example, the pigmentation gene MC1R acts as a modifier
gene and influences the risk of malignant melanoma in both
carriers and non-carriers [10]. Norway has among the
highest incidences in the world of malignant melanoma
with an accumulated risk up to the age of 75 of 2.4 % for
both genders [11], while mutations in CDKN2A and CDK4
were only found in 6.9 % in a population-based study
among individuals with multiple primary melanomas
(MPM) [12]. As a result, there are many families in our
clinic that show numerous cases of malignant melanoma
probably due to shared skin types and shared tanning
practices where we cannot identify a mutation.
There are different observations of which other cancer
types are associated with mutations in CDKN2A. Goldstein
et al. [13] found that the risk of pancreatic cancer for
CDKN2A mutation-carriers was 22-fold compared to the
general population. This increase was not observed in
melanoma kindreds without a demonstrated mutation. The
Dutch founder mutation in CDKN2A, called ‘‘p16-Leiden’’,
is reported to confer the highest known lifetime risk of
developing pancreatic cancer of about 17 % [14]. On the
other hand, pancreatic cancer was not found to be associ-
ated with CDKN2A mutations in a GenoMel study from
Australia [15]. This could be caused by genotype/pheno-
type differences. There are several reports of increased
risks of other cancer types in CDKN2A-families in addition
to pancreatic cancer [16–19]. One prospective study from
Sweden found an especially increased risk of cancer of the
pancreas, upper digestive and respiratory tissues in carriers
of the Swedish founder mutation (p.Arg112dup) who had
smoked [18]. Potjer et al. [19], through another prospective
study of the p16-Leiden cohort, found an increased risk
among tobacco users of cancers in the pancreas, respiratory
tract and head and neck.
We have previously reported on information-flow in
families with BRCA1 mutations [20]. At that time, there
had recently been passed a law in Norway determining that
health workers were not allowed to approach and contact
potential carriers of genetic mutations. The reported study
was undertaken for the purpose of evaluating this law. We
examined whether genetic information reached those at
risk by only inviting other family members to contact us
through our patients. We found that in our population, only
3 % of at-risk adult females did not contact us during the
study period (conferring a 97 % uptake of genetic ser-
vices). After communicating with our patients, it was
established that the 3 % had, indeed, been given the
information of our services. This indicated that it was the
non-responders’ own decision not to have contacted us and
that the system of having the patients inform their own
relatives functioned as a way of spreading information
throughout families.
Adherence to surveillance recommendations has been
studied in many hereditary cancer syndromes. In a report
by Stoffel et al. [21] of Americans in families with col-
orectal cancer with or without an identified mismatch-re-
pair (MMR) mutation, 73 % followed their recommended
program of colonoscopies every two years. The data was
gathered through self-reported questionnaires. There is a
possibility that responders to the questionnaire have a
higher compliance rate than those who chose not to reply.
Li-Fraumeni syndrome (LFS) is different in that there are
no established complete periodic screening recommenda-
tions due to the range of tumor locations and ages of onset.
Yet, in a study on subjects with at least a 50 % risk of
having LFS, 78 % of them responded that they complied
with the screening options that had been recommended to
them. The type of screening was not universal, but organ-
targeted screening based upon the cancers in their family.
This study was also based upon self-reporting [22].
There are few publications on surveillance in families at
risk of CMM. In a report from Australia [23], 166
CDKN2A mutation carriers were asked about their
surveillance practices, both skin self-examination and
clinical skin-examination. Overall, 21 % of them per-
formed skin self-examination monthly, while 43 % repor-
ted having had a clinical skin-examination in the last
12 months. Only 17 % adhered to their recommendations
of performing clinical skin-examination twice a year.
In a study published in 2008, Aspinwall et al. [24]
showed that the intention to undergo both clinical screen-
ing and self-examination increased along with photo-pro-
tection behavior after disclosure of CDKN2A mutation
status. In that study, the participants had previously been
informed of the benefits and recommendations of regular
screening. Still, before disclosure of their genetic results,
only 52 % had received a total body skin examination
within the last year. Those with at personal history of
melanoma were more compliant at 78 %. Learning of their
mutation status improved the overall intention to follow
recommendations of total body skin examination and skin
self-examination in all groups. Even among the mutation-
negative participants, compliance with the recommended
skin self-examination increased; thus, undermining the
notion that a normal test result will give a false sense of
security.
In the current study, we compare our knowledge of
families with a CDKN2A mutation with our previous
experiences in families with BRCA mutations. We describe
uptake of contacting us as a way to gauge whether our
methods of communication with our patients in the clinic
also work in families with hereditary malignant melanoma
(uptake of genetic counseling). It is also a goal of the
current report to study individuals’ interest in genetic
testing (uptake of genetic testing). We look at the
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differences in these parameters between males and females,
since mutations in CDKN2A, as far as we know, give
similar CMM risks to both genders, unlike BRCA muta-
tions. We also wish to determine if carriers of CDKN2A
mutation follow our recommendation of yearly dermato-
logical examinations (uptake of surveillance).
Materials and methods
Patients and recruitment
The probands included in this study had all been diagnosed
with at least two primary malignant melanomas and they
all carried a mutation in CDKN2A. They were referred to
us in February 2008 after the conclusion of a separate,
population-based project which aimed to describe the
prevalence of hereditary malignant melanoma in Norway.
The inclusion criteria and results of that project were
described in detail elsewhere [12]. In short, all living
individuals who had been registered in the Cancer Registry
of Norway with MPM between the years 1953 and 2004
were invited to participate. Blood was collected for genetic
testing of CDK4 and CDKN2A. Disease-causing mutations
were found in 6.9 % [12]. Following the conclusion of that
project, nineteen CDKN2A carriers were referred to us for
genetic counseling and follow-up. This cohort will be
referred to as probands. Once they were referred to us, they
were incorporated into our regular cancer genetics clinic.
All persons in our clinic are referred to as patients,
regardless of disease status. Two among the 19 probands
were father and son, so in total there were 18 separate
families with 7 different disease-causing mutations in
CDKN2A. Those with mutations in CDK4 were referred to
another genetics clinic in Western Norway and were not
included in the current study.
Probands
After the 19 probands had been referred to us, we sent them a
letter with an appointment for genetic counseling. All had
previously been informed by the dermatologist running the
project that they harbored a mutation in CDKN2A [12].
Genetic counseling sessions included drawing a detailed
family history, discussing basic relevant genetics and
inheritance, sharing information on risks associated with
carrying amutation inCDKN2A, including that of pancreatic
cancer risk and sun-tanning behavior. Probands also received
the option of annual dermatological examinations. In addi-
tion, we received written permission to confirm relevant
diagnoses from hospital files or the Cancer Registry of
Norway, both for the probands and their deceased, affected
relatives. During the first counseling session, we identified
the relatives that should be informed of the possibility of
genetic counseling, genetic testing and potentially derma-
tological surveillance. The probands were given sheets with
information to give to these relatives and contact forms for
them to fill out and return to us. We are, by law, not allowed
to contact at-risk persons who have not been in touch with us
first and we are, therefore, dependent upon the patient to
reach and inform their own family members. We did not
make assumptions regarding from which side of the family
the mutation may have originated, but we started on the side
affected with malignant melanoma or pancreatic cancer. At
that first consultation, a blood sample was collected to con-
firm the proband’s carrier status.
Five out of the 19 probands either did not show up for
genetic counseling or cancelled their appointment. A phone
call to each of them revealed different reasons for not
wanting an appointment. During the phone interview we
drew a family history and identified the relatives who should
receive information regarding our services. All probands
indicated that they would contact these relatives. Following
the conversation, information and documentation were
mailed to these five probands. They also received informa-
tion and contact materials to pass on to their relatives.
Relatives
The relatives who contacted us by returning the form given
to them by the probands were given genetic counseling.
Their place in the pedigree was determined and the risk of
carrying the particular mutation in CDKN2A established.
We counseled them of relevant genetics, the risks associ-
ated with the mutation and sun-exposure. The relatives
were also informed of the potential risk of pancreatic
cancer and of our inability to provide efficient regular
surveillance of the pancreas to ensure early diagnosis.
All patients, both probands and their relatives, were
counseled by the same genetic counselor. All were given
the same information regarding cancer risk for both
malignant melanoma and pancreatic cancer. Only one
family carried a truncating mutation, yet the information
given was not differentiated.
All were offered genetic testing, except those coming to
the counseling session together with a parent who had not
yet been tested. When the genetic tests were completed, all
received a neutral letter for a new appointment. They had
to return to the clinic for their results, where another blood
sample was tested for confirmation of the genetic results.
These elements are standard procedures in our clinic.
Uptake definition
We determined the primary and secondary uptake of
genetic services. We defined ‘‘primary uptake’’ as the
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proportion of the probands’ first-degree relatives (FDR)
(alive and above 18 years of age) who contacted us. When
we tested all the relatives who contacted us, some turned
out to harbor the mutation in the family. Once they knew of
their results, they became the new index person in a
‘‘secondary uptake’’. They, in turn, informed their own
FDR of the possibility of genetic testing, counseling and
surveillance. The fraction of those new FDR who contacted
us was defined by us as the ‘‘secondary uptake’’. Each
person was only counted once, so, for example, a proband
was not counted as a relative to the new index person, even
if they may be FDR. A flowchart depicting primary and
secondary uptake is shown in Fig. 1.
We only included those index persons who had been
given their genetic testing results prior to December 31,
2010, and counted only the relatives who contacted us prior
to December 31, 2011. Thereby, allowing a minimum of
one year for a relative of an index person to contact us.
We were very strict with the inclusion criteria for uptake.
There were cases where a potential FDR did not contact us,
but his/her children contacted us instead. The reason could
have been that the FDR was ill, old or deceased; we still did
not include the children as FDR, and theywere not counted in
our uptake of genetic counseling estimates. Only if the
children turned out to bemutation carriers were they counted
and then only as index persons in our ‘‘secondary uptake’’.
Surveillance
In contrast with many of the reports on surveillance, we
refer our own patients to their initial follow-up
appointment, thereby, not relying on the patients or other
physicians to do so.
Probands and their relatives with mutations were offered
and referred to yearly skin examinations at a regional
hospital dermatological department. For many, this
required traveling long distances. In many cases, we were
able to find a satisfactory surveillance program closer to
their home. We plan to report on the results of the
surveillance of our patients at a later date.
Statistical analysis
To explore the level of significance of the observed dif-
ferences between the groups (Table 2), we used v2 test
(IBM SPSS Version 22).
Ethics
All activities were part of the Norwegian public health-care
system. All who proceeded with a genetic test were
required to sign an informed consent form, as is standard
for all predictive testing in a clinical setting in Norway. All
patient materials were kept in our medical files. No named
information was exported from the medical files and no
separate research registry including patient names was
established.
Results
By December 31, 2011, the 19 probands from 18 kindreds
had been counseled and instructed to give information to
their relatives about the possibility of genetic services. 133
of them had stepwise contacted us in writing. This included
FDR to our probands, but there were also others who were
more distantly related. All were given an appointment for
genetic counseling.
An overview of all the mutation carriers, their mutations
and information regarding the melanomas and pancreatic
cancers is depicted in Table 1.
Uptake of genetic counseling
The probands had 77 FDR of which 49 contacted us (64 %)
during the study period (Fig. 1). Our secondary uptake
showed that 46 out of a possible 67 FDRof the emerging new
mutation carriers contacted our clinic (69 %) (Fig. 1). There
was no significant difference between the primary and sec-
ondary uptake (p[ 0.5) andwe, therefore, combined the two
groups (Table 2; Fig. 1). Combining the primary and sec-
ondary uptakes, we obtained a total uptake of 66 % (95/144).
Seventy-seven percent of the female FDR compared to
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Fig. 1 Uptake of genetic counseling
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period, thereby showing a highly significant gender dif-
ference (p = 0.003; Table 2).
Uptake of genetic testing and genetic results
All of the 133 relatives who contacted us seeking genetic
services were given a genetic counseling appointment. Of
these, 128 were offered genetic testing. Those who were
not offered testing were individuals where either their
parents turned out not to carry the family’s mutation or
they did not turn up for their genetic counseling appoint-
ment. Only two individuals at risk decided that they did not
want genetic testing following genetic counseling, giving a
98 % uptake of genetic testing (126/128).
In total, 70 received results that they did not carry the
mutation in their family, while 56 harbored the mutation in
CDKN2A. Among all FDR, 95 individuals, only one
decided not to proceed with genetic testing. Of the
remaining 94, 52 (55 %) individuals had the mutation,
while 42 (45 %) found out that they did not carry the
mutation found in their FDR. Uptake of genetic testing and
the results of testing are shown in Fig. 2.
Uptake of surveillance (compliance)
All nineteen probands had the opportunity to attend our
regular surveillance program. Three had died, two of which
from pancreatic cancer. Three probands did not, to our
knowledge, attend any surveillance program. Two of them
had cancelled their appointment, while one indicated he
was too old. One was followed by her primary doctor due
to an unrelated, debilitating condition. Three decided to
continue surveillance at a local hospital. In total, thirteen
probands wanted follow-up, which indicated a total com-
pliance of 81 % (13/16).
By December 31, 2011, 56 relatives had been tested and
determined to be mutation carriers of the family’s mutation
in CDKN2A. In this group, two declined the option of
yearly skin surveillance. In the remaining group, one had
died of malignant melanoma diagnosed prior to our













c.79G[T p.Glu27X 1 7 (1) 2 (1) 4 (2) 47–55 (47–51)
c.159G[C p.Met53Ile 7 33 (7) 11 (7) 32 (22) 31–72 (31–68) Panc (2)
c.242C[G p.Pro81Arg 2 9 (2) 6 (2) 9 (6) 33–64 (41–64) Panc (2)
c.259C[T p.Arg87Trp 2 2 (2) 2 (2) 5 (5) 28–53 (28–53)
c.353C[T p.Ala118Val 4 15 (4) 5 (4) 12 (11) 34–79 (40–79)
c.379G[C c.Ala127Pro 1 2 (2) 2 (2) 7 (7) 34–76 (34–76)
c.392G[C c.Arg131Pro 1 7 (1) 4 (1) 6 (3) 16–38 (19–38)
Table 2 Uptake of genetic
counseling with gender
distribution
Contact (%) No contact (%) Total
1 Uptake 2 Uptake Total 1 Uptake 2 Uptake Total
Females 29 (71) 31 (84) 60 (77) 12 (29) 6 (16) 18 (23) 78
Males 20 (56) 15 (50) 35 (53) 16 (44) 15 (50) 31 (47) 66
Total 49 (64) 46 (69) 95 (66) 28 (36) 21 (31) 49 (34) 144
19 probands
133 total relatives 
contacted clinic
(49 FDR)









Fig. 2 Uptake of genetic testing
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contact. Another person lived abroad and received a letter
in English from us explaining our surveillance recom-
mendations. One had attended appointments on his own as
part of the follow-up of his malignant melanoma diagnosis,
also previously diagnosed. Referrals were given to the
remaining individuals. With only two mutation-positive
relatives declining follow-up, compliance with surveillance
in this group was 96 % (53/55). The results of the uptake of
surveillance are shown in Table 3.
All FDR with a personal history of malignant melanoma
contacted us within the time of the study and all proceeded
with genetic testing. All had the mutation in the family.
Discussion
In this study of families with a CDKN2A mutation, we have
reported their interest in genetic services by studying if
they come when invited, if they want genetic testing and
whether they adhere to our surveillance program. In gen-
eral, we found a relatively high uptake across all parame-
ters compared to studies published from other populations.
Uptake of genetic counseling
During our study period, 66 % (95/144) of all FDR of
mutation carriers contacted us (overall uptake of genetic
counseling). Originally, we had expected that the first
group of FDR (primary uptake), those closest to the pro-
bands, would be more motivated to contact us than the next
wave of relatives. All in the first group would, by defini-
tion, have a close relative with at least two bouts of
malignant melanoma, which was not always the case in the
second group. We had, therefore, separated our FDR into
two groups, those who were FDR of our initial probands
(primary uptake) and those who were FDR to the emerging
group of mutation carriers (secondary uptake). These two
groups turned out not to be significantly different with
regard to uptake and gender distribution, and they were,
therefore, combined (Table 2). One reason why these two
groups are not as different as anticipated, might be that the
presence of disease is not the determining factor why
people seek genetic services, but the knowledge of the
presence of the mutation is, which is equal in both groups.
The uptake of genetic counseling is high but still much
lower than our previous experience in BRCA1 families
(97 %) [6]. The reasons for this discrepancy could be
many, but may have something to with the way the initial
participants were ascertained. The current investigation
originated from a research project [12]. The participants
were contacted by researchers and asked if they wanted
genetic testing based on the fact that they had developed
MPM. The BRCA study, on the other hand, originated from
individuals who had initiated contact with our clinic
themselves searching for help to determine the cause of
breast and ovarian cancer in their families.
Another reason why the CDKN2A and BRCA families
behaved differently may be that all the probands in the
current study had, by definition, survived their cancers. In
fact, most affecteds in these families had not died from
their diagnoses of malignant melanoma, It is possible that
there was a perception that malignant melanoma is not such
a ‘‘dangerous’’ condition, thus genetic testing was not that
important. This is in contrast with our BRCA1 families
where a large percentage of the affected relatives had died
from their disease.
There were mutation carriers where none of their FDR
had contacted us. We knew from our phone interviews with
those probands the number and gender of their FDR. Since
these were large families, we found it strange that no-one
had been interested in our services. We suspected that our
contacts had not informed their relatives, thereby not
allowing these relatives to decide for themselves whether
to contact us or not. There was also one index person in our
secondary uptake, where no-one from his large family
contacted us. Because of the large sizes of these families,
this reduced our combined uptake of genetic counseling
drastically. If we had omitted the FDR from these three
probands and one index person, the total uptake would
have increased from 66 to 80 % (95/119).
We have, indeed, after the project was concluded, been
informed that the relatives of one of the three probands
whose families had not contacted us, found the papers from
our clinic after the proband’s death. These relatives con-
firmed that their uncle had never mentioned anything to
them about the presence of a mutation in their family.
The probands whose families did not contact us were all
part of the group who chose not to come to the genetic
counseling session in person. They only received a phone
call. They had indicated that they would inform their rel-
atives of our services, but did not. It may be that those
patients who cancelled their opportunity to talk to us in
person were, in fact, never interested, neither for their own
sake nor for their relatives; thereby not letting their rela-
tives decide for themselves. We did not contact our patients
to question them as to the reasons we had not heard from
any of their relatives. All of those individuals whose
Table 3 Uptake of surveillance
Surveillance (%) No surveillance Total
Proband 13 (81) 3 16
Relatives (Mut?) 53 (96) 2 55
Total 66 (93) 5 71
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relatives did not contact us had been diagnosed with
malignant melanoma.
How and if genetic information is communicated within
a family is related to many aspects. It will be influenced by
the proband’s own perceptions of the disease and how well
it may be diagnosed and treated. It will also be influenced
by the relationship to his/her family members, where close
relations, both biological and/or social, are more likely to
be informed and in the end, tested for the mutation in the
family.
Our experiences in the current study in CDKN2A fam-
ilies have both similarities and differences from our own
previous observations and conclusions in BRCA1 families
[6, 20]. In both groups the uptake was higher than descri-
bed in most other reports. However, we cannot assume that
the information about our services and the potential of risk
reached all FDR even though our contacts indicated that
they would inform their next of kin. These may be exam-
ples of ‘‘passive non-disclosure’’, first described by Gaff
et al. [25, 26] in families with HNPCC (hereditary non-
polyposis colon cancer). These are situations in genetic
counseling where patients imply that they will communi-
cate information regarding genetic risk to their relatives,
but do not. This is different from ‘‘active non-disclosure’’
where patients openly admit that they do not intend to
contact other family members. Gaff et al. [25, 26] indicated
that this may have different causes including that the index
person assumes that the information is not relevant to some
or all family members.
We found a significant gender difference in uptake of
genetic counseling and females were more likely to contact
us. We saw the same trend in families with a BRCA1
mutation, but had concluded at that point that the probable
reason was the cancer-risk difference. Male BRCA1-carri-
ers have a close to normal cancer risk. Female carriers, on
the other hand, have a significant risk of developing breast
or ovarian cancer during their lifetime. We offer them
information and referrals to different procedures, including
prophylactic surgeries, which will significantly increase
their chance of survival. With CDKN2A, on the other hand,
there is no known gender difference with regard to cancer
risk. The gender difference in uptake may, therefore, show
that females are, indeed, more likely to seek health services
when indicated, or at least, that they do so more promptly.
The reasons for this may be many, but one might be that
women often feel more responsible for the health of her
family members and herself. Females have previously been
named the ‘‘housekeepers’’ of genetic information in the
family, in that they talk more about cancer in the family
and are the main keepers of information even when the
genetic risk is on their husbands’ side [27].
Uptake of genetic testing
Even though 66 % uptake of genetic counseling among
FDR is low compared with 97 % among at-risk females in
BRCA families, almost all who did contact us for the cur-
rent study proceeded with genetic testing. This may indi-
cate that in this current group, most made their decision
whether to proceed with genetic testing or not, prior to
contacting us. They may not perceive genetic counseling as
a deciding factor in the decision-making process. It seems
that the information given to them through the genetic
counseling process confirmed their decision to pursue
testing. This is different from our families with a BRCA1
mutation where 97 % contacted us, while only 82 % of
them pursued testing. This difference could also be a
measure of how genetic testing has become more accepted
in more recent years.
In a publication from Australia, Forrest et al. [28] looked
at the uptake of genetic testing in four non-cancer syn-
dromes with different heritance patterns; chromosomal
translocations, fragile X syndrome, Huntington syndrome
(HD) and spinal muscular atrophy. They found that uptake
of genetic testing among FDR spanned from 45 % for HD
to 79 % for Fragile X. This shows that the genetic condi-
tion and its implications do make a difference when it
comes to decisions on whether to proceed with genetic
testing. Interestingly, Forrest et al. saw only a gender dif-
ference in uptake of testing for Fragile X, where females
were significantly more likely to pursue testing to learn of
their genetic status; not surprising given the X-linked
inheritance pattern with this condition [28].
Uptake of surveillance
We see that uptake of surveillance with annual skin
examinations by a dermatologist at a university hospital
was very high as compared with other studies [23, 24]. In
this study, the highest adherence was observed among the
mutation-positive relatives (96 %), compared to the pro-
bands (81 %). It may be surprising that not all of the
probands, who by definition have had malignant melanoma
at least twice, wished to be examined regularly, but many
in the group that declined follow-up referred to their old
age as a contributing factor. The high adherence to uptake
of surveillance might be related to the fact that health
treatment and follow-up are paid for by the state in Norway
and that our patients trust that the program for following
moles is effective in preventing malignant melanoma. Skin
examinations are also non-invasive and pain-free in com-
parison to the screening for many of the other hereditary
cancers.
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Study limitations
In our group of relatives there were both individuals with a
previous diagnosis of malignant melanoma (and other
cancers) and individuals without cancer. Ascertainment
may have been influenced by the possibility that affecteds
were more likely to contact us when invited than others.
All relatives with a personal history of malignant mela-
noma who contacted us had the mutation in the family.
We do not know whether our findings are representative
for other populations since these findings are dependent
upon how genetic services are funded and upon family
structures.
Conclusions
In conclusion, we have found there to be a generally high
uptake of all aspects of genetic services in CDKN2A-
families as they were in BRCA1 families. Our results
indicate that most people seek a resolve regarding genetic
status even if we are not able to provide surveillance for all
cancer risks, such as pancreas cancer. Females were sig-
nificantly more likely to participate regardless of the family
having a mutation in CDKN2A or BRCA1. Even though our
uptake was high there were a few individuals who did not
seem to inform their relatives at all. We believe that all
clinical work should systematically be evaluated and
monitored. This will provide valuable and necessary
knowledge for the future.
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